In this episode, James Davis, PharmD, BCOP and Victoria Nachar, PharmD, BCOP summarize the latest key clinical updates on BTK inhibitors in CLL based on data recently presented at the annual ASCO and EHA meetings, including: The randomized phase III FLAIR trial The randomized phase III SEQUOIA trial The randomized phase III BRUIN CLL-321 trial Presenters: James Davis, PharmD, BCOP Clinical Pharmacy Specialist, Malignant Hematology MUSC Hollings Cancer Center Assistant Professor MUSC College of Pharmacy Charleston, South Carolina Victoria Nachar, PharmD, BCOP Clinical Pharmacist Specialist, Hematology University of Michigan Rogel Cancer Center Ann Arbor, Michigan Link to full program: https://bit.ly/3H2EcSX Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
